Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Norovirus GII.4 major capsid protein VP1 (VP1)
- Target
- VP1
- Molecular classification
- Viral structural protein, Capsid protein, Antigen, Viral protein
01
Overview
Norovirus GII.4 major capsid protein VP1 is the principal structural protein encoded by ORF2 in human noroviruses of genogroup II, genotype 4. VP1 features a modular architecture with an N-terminal arm (NTA), shell (S) domain forming the icosahedral shell, and a protruding (P) domain divided into P1 and P2 subdomains, distinguished by a flexible hinge region. The P2 subdomain is the most exposed and variable, mediating host attachment by binding to histoblood group antigens and containing antigenic determinants for neutralizing antibodies and immune escape. VP1 assembles into T=3 or T=4 icosahedral capsids in virus-like particles and native virions. GII.4 VP1's conformational and sequence variability drive frequent emergence of antibody escape mutants and epidemic variants, making it a critical target for norovirus vaccine development and molecular epidemiology.
- Other names
- Major capsid protein VP1GII.4 VP1Norovirus VP1
02
Mechanism of action
Neutralizing antibody binding (epitope recognition, immune blockade); vaccine-mediated immune response via presented viral antigens
03
Biological functions
Viral capsid formationCell attachment (host receptor binding via histoblood group antigens)Immune evasion (mutation-driven antigenic variation in the P2 domain)Antigen presentation
04
Disease associations
Infection (principal cause of epidemic and sporadic acute viral gastroenteritis worldwide)Immune escape (epitope variation leading to outbreak persistence)
05
Safety considerations
Highly variable antigenic sites (especially in P2 domain) can result in immune escape and reduced vaccine efficacyConformational flexibility may limit sustained antibody targeting
06
Interacting drugs
No approved direct-acting drugs currently
2 more in the full profile.
07
Biomarkers
VP1 sequence and antigenicity are used to genotype noroviruses and monitor outbreak strainsPresence of epitopes in P2 domain can indicate immune escape and epidemic potential
Beyond the preview
Go deeper on Norovirus GII.4 major capsid protein VP1 (VP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Norovirus GII.4 major capsid protein VP1 (VP1).